NIH

During a Wednesday Senate budget hearing, Francis Collins, director of the National Institutes of Health (NIH) expressed positive remarks about the therapeutic potential of psychedelics such as psilocybin and MDMA. “I think as we’ve learned more about how the brain works...

One of the key doctors leading the novel coronavirus (COVID-19) pandemic response at the federal level said he was fired from his job because he resisted the use of antimalarial drugs touted by President Donald Trump. What Happened Director of the Biomedical Advanced Research and Development...

Through “stateless” subsidiaries and shadow companies, Apple Inc. (NASDAQ: AAPL) amassed $252 billion in offshore cash subject to foreign tax rates far lower than the U.S.’s 35 percent, according to BBC News. In 2017 alone, the firm made $44.7 billion outside the U.S. and...

Neither Republicans nor Democrats are eager to cut the National Institutes of Health funding by the president’s suggested $5.8 billion, but with the proposal still on the table, the sum is not yet safe. And as 18 percent of the current $31.7 billion budget hangs in the balance, more Americans...

Congressional Republicans and Democrats joined forces on Thursday to pass the 21st Century Cures Act, a comprehensive piece of healthcare legislation that provides funding for researching some of America’s biggest health concerns. Senate Vote 94–5 The legislation passed a Senate vote 94...

Last Tuesday, Heat Biologics Inc (NASDAQ: HTBX) announced its collaboration with the University of Miami to research a Zika virus vaccine. The research will implement the existing gp96 platform. Essentially, gp96 is a molecule present in all human cells, which interacts with proteins to trigger an...

HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...

In a story first reported by Nikkei and updated recently by Le Monde, Sony Corp. (NYSE: SNE) and U.S. genome sequencing equipment maker Illumina Inc. (NASDAQ: ILMN) plan to launch a human genome analysis project in October. The project will involve the study and analysis of genetic material...